Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANCE Part A: Ozanimod in Relapsing Multiple Sclerosis
NCT01628393Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Sep 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of ozanimod in multiple sclerosis (MS), sponsored by Celgene Corporation. Started Sep 2012; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01628393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01628393.